Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

INTRODUCTION: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors – afatinib, erlotinib, icotinib, and gefitinib – are available for first-line treatment of NSCLC in China; however, there a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Long, Xu, Chong-Rui, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Shi, Jian Hua, Märten, Angela, Fan, Jean, Peil, Barbara, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280988/
https://www.ncbi.nlm.nih.gov/pubmed/30584317
http://dx.doi.org/10.2147/OTT.S160358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280988/
https://www.ncbi.nlm.nih.gov/pubmed/30584317
http://dx.doi.org/10.2147/OTT.S160358

Ejemplares similares